https://en.wikipedia.org/wiki/Hydroxychloroquine
> Several countries initially used chloroquine or hydroxychloroquine for treatment of persons hospitalized with COVID-19 (as of March 2020), though the drug was not formally approved through clinical trials. From April to June 2020, there was an emergency use authorization for their use in the United States, and was used off label for potential treatment of the disease.
https://www.fda.gov/media/136534/download is the FDA issuing an EUA in late March.
April 8: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207200/
> As we await further evidence on the role, if any, of these drugs in addressing the SARS-CoV-2 pandemic, many clinicians have already begun using them to treat COVID-19.
> A surge in prescriptions based on speculation about their role in the prevention or treatment of SARS-CoV-2 infection threatens the availability of these drugs for patients with chronic inflammatory disorders for whom they are known to be effective. At least 2 manufacturers have announced plans to increase hydroxychloroquine production in anticipation of this need.
I think we’re done here.